Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Pr...
Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells
About this item
Full title
Author / Creator
Stagno, Matias Julian , Zacharopoulou, Nefeli , Bochem, Jonas , Tsapara, Anna , Pelzl, Lisann , al-Maghout, Tamer , Kallergi, Galatea , Alkahtani, Saad , Alevizopoulos, Konstantinos , Dimas, Konstantinos , Calogeropoulou, Theodora , Warmann, Steven W. , Lang, Florian , Schmid, Evi and Stournaras, Christos
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Abstract
Background/Aims: Istaroxime is a validated inotropic Na+/K+ ATPase inhibitor currently in development for the treatment of various cardiac conditions. Recent findings established that this steroidal drug exhibits potent apoptotic responses in prostate tumors in vitro and in vivo, by affecting key signaling orchestrating proliferation an...
Alternative Titles
Full title
Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_28704809
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_28704809
Other Identifiers
ISSN
1015-8987
E-ISSN
1421-9778
DOI
10.1159/000479200
